Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

(2022) Jennifer B. Shah et al.   Nature Communications

Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance

(2020) Stephen J. Pettitt et al.   Cancer Discovery

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance

(2020) L. Tobalina et al.   ANNALS OF ONCOLOGY

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations

(2020) Talayeh S. Ghezelayagh et al.   GYNECOLOGIC ONCOLOGY

Molecular profiles of BRCA1‐associated ovarian cancer treated by platinum‐based therapy: Analysis of primary, residual and relapsed tumors

(2019) Anna P. Sokolenko et al.   INTERNATIONAL JOURNAL OF CANCER

ATL

(2018) Tatyana V. Gorodnova et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

(2018) Kevin K Lin et al.   Cancer Discovery

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation

(2015) Tatiana V. Gorodnova et al.   CANCER LETTERS

Genomic profile of ovarian carcinomas

(2014) Francesca Micci et al.   BMC CANCER

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolutionary Pathways in BRCA1-Associated Breast Tumors

(2012) Filipe C. Martins et al.   Cancer Discovery

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer

(2009) H. Holstege et al.   CANCER RESEARCH